Galderma will start by assessing AstraZeneca candidates for other indications.

AstraZeneca and Galderma Pharma are joining forces to develop treatments for dermatological conditions. Galderma will evaluate compounds from AstraZeneca’s existing pipeline for their potential to treat a range of skin diseases like acne, atopic dermatitis, and psoriasis.

According to the deal Galderma will have exclusive access to a number of AstraZeneca’s compounds. Initial targets have already been identified from disease areas as diverse as oncology, inflammation, and central nervous system disorders.

“This partnership is an example of how we are leveraging our science in new and creative ways through collaborations with recognized experts outside of AstraZeneca’s core therapy areas,” notes Clive Morris, head of the new opportunities innovative medicines unit at AstraZeneca. “Partnering with Galderma, a world leader in dermatology, is the most efficient and effective way to unlock the potential of our compounds in this rapidly evolving disease area.”

Galderma was founded in 1981 and has 31 affiliates around the world. The firm says that it invests approximately 20% of its sales each year to discover and develop new products and access innovative technologies. The company’s laboratory in Sophia-Antipolis is focused exclusively on dermatology.

Previous articleTracking NIH Grants in 2010
Next articleRainDance Forges Separate Pacts with Ambry and Roche to Advance ADME Analysis